You can access the original SEC filing by clicking here.
Ownership Summary Table
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
BioTime, Inc. S.S. OR | 21,747,569 | 0 | 21,747,569 | 0 | 44.4% |
Page 1 of 7 – SEC Filing
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
SCHEDULE
13D
Under
the Securities Exchange Act of 1934
(Amendment
No. 5)
ASTERIAS
BIOTHERAPEUTICS, INC.
(Name
of Issuer)
Series A Common Stock, par value $0.0001 per share | 04624N 107 | |
(Title of class of securities) | (CUSIP number) |
Russell
Skibsted
Chief
Financial Officer
BioTime,
Inc.
1010
Atlantic Avenue
Suite
102
Alameda,
California 94501
(510)
521-3390
(Name,
address and telephone number of person authorized to receive notices and communications)
March
28, 2017
(Date
of event which requires filing of this statement)
If
the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule
13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ].
Note:
When filing this statement in paper format, six copies of this statement, including exhibits, should be filed with the Commission.
See Rule 13d-1(a) for other parties to whom copies are to be sent.
(Continued
on following page(s))